Cytokines in chronic rheumatic diseases: Is everything lack of homeostatic balance?

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Chizzolini, Carlo ^a   Dayer, Jean Michel ^b   Miossec, Pierre ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMERIN 15; CHEMERIN 9; CXCL1 CHEMOKINE; CYTOKINE; DICKKOPF 1 PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DEATH; HOMEOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; METABOLISM; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; TISSUE INJURY; TISSUE REPAIR; IMMUNOLOGY; RHEUMATIC DISEASE;

CYTOKINES; HOMEOSTASIS; HUMANS; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 75649128017     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2767     Document Type: Review

References (71)

1. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33:305-315. 10.1002/art.1780330302, 2180403.
2. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18. 10.1111/j.1600-065X.2008.00701.x, 19161412.
3. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, Muzio M, Bergottini R, Scanziani E, Vecchi A, Hirsch E, Mantovani A. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004, 101:3522-3526. 10.1073/pnas.0308680101, 373495, 14993616.
4. Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008, 205:1879-1888. 10.1084/jem.20072646, 2525585, 18644972.
5. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA, Donath MY. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci USA 2004, 101:8138-8143. 10.1073/pnas.0305683101, 419570, 15141093.
6. Molnarfi N, Gruaz L, Dayer JM, Burger D. Opposite regulation of IL-1β and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccharides or contact with T cells. J Immunol 2007, 178:446-454.
7. Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D. Differential regulation of cytokine production by PI3Kδ in human monocytes upon acute and chronic inflammatory conditions. Mol Immunol 2008, 45:3419-3427. 10.1016/j.molimm.2008.04.001, 18471882.
8. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil SS, Lalive PH. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009, 106:4355-4359. 10.1073/pnas.0812183106, 2649955,2649955, 19255448.
9. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196. 10.1146/annurev.immunol.19.1.163, 11244034.
10. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008, 223:7-19. 10.1111/j.1600-065X.2008.00626.x, 18613827.
11. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545. 10.1172/JCI36389, 2575731, 18982160.
12. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/annurev.immunol.23.021704.115806, 15771564.
13. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
14. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989, 264:11966-11973.
15. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH, Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996, 183:1399-1406. 10.1084/jem.183.4.1399, 2192475, 8666898.
16. Knupfer H, Preiss R. sIL-6R: more than an agonist?. Immunol Cell Biol 2008, 86:87-91. 10.1038/sj.icb.7100113, 17724457.
17. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998, 161:6347-6355.
18. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
19. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
20. Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007, 97:755-762.
21. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 2006, 6:907-918. 10.1038/nri1964, 17124512.
22. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621. 10.1056/NEJMra052723, 16467548.
23. Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, Lu ZH, Hesselgesser J, Horuk R. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 1995, 181:1311-1317. 10.1084/jem.181.4.1311, 2191961, 7699323.
24. Gardner L, Patterson AM, Ashton BA, Stone MA, Middleton J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem Biophys Res Commun 2004, 321:306-312. 10.1016/j.bbrc.2004.06.146, 15358176.
25. Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol 2002, 71:141-153. 2665273, 11781390.
26. Addison CL, Belperio JA, Burdick MD, Strieter RM. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004, 4:28. 10.1186/1471-2407-4-28, 459224, 15214968.
27. Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001, 158:867-877. 1850343, 11238036.
28. Jamieson T, Cook DN, Nibbs RJ, Rot A, Nixon C, McLean P, Alcami A, Lira SA, Wiekowski M, Graham GJ. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 2005, 6:403-411. 10.1038/ni1182, 15750596.
29. Martinez de la Torre Y, Locati M, Buracchi C, Dupor J, Cook DN, Bonecchi R, Nebuloni M, Rukavina D, Vago L, Vecchi A, Lira SA, Mantovani A. Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur J Immunol 2005, 35:1342-1346. 10.1002/eji.200526114, 15789340.
30. Martinez de la Torre Y, Buracchi C, Borroni EM, Dupor J, Bonecchi R, Nebuloni M, Pasqualini F, Doni A, Lauri E, Agostinis C, Bulla R, Cook DN, Haribabu B, Meroni P, Rukavina D, Vago L, Tedesco F, Vecchi A, Lira SA, Locati M, Mantovani A. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007, 104:2319-2324. 10.1073/pnas.0607514104, 1892950, 17283337.
31. Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, Graham GJ. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 2007, 117:1884-1892. 10.1172/JCI30068, 1904306, 17607362.
32. Heinzel K, Benz C, Bleul CC. A silent chemokine receptor regulates steady-state leukocyte homing in vivo. Proc Natl Acad Sci USA 2007, 104:8421-8426. 10.1073/pnas.0608274104, 1895965, 17485674.
33. D'Amico G, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A, Sozzani S, Allavena P, Mantovani A. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 2000, 1:387-391. 10.1038/80819, 11062497.
34. Cash JL, Hart R, Russ A, Dixon JP, Colledge WH, Doran J, Hendrick AG, Carlton MB, Greaves DR. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008, 205:767-775. 10.1084/jem.20071601, 2292217, 18391062.
35. Zabel BA, Nakae S, Zuniga L, Kim JY, Ohyama T, Alt C, Pan J, Suto H, Soler D, Allen SJ, Handel TM, Song CH, Galli SJ, Butcher EC. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med 2008, 205:2207-2220. 10.1084/jem.20080300, 2556791, 18794339.
36. Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TA, Bond MW, Moore KW, Sher A, Fiorentino DF. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev 1991, 123:209-229. 10.1111/j.1600-065X.1991.tb00612.x, 1684780.
37. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991, 12:256-257. 10.1016/0167-5699(91)90120-I, 1680337.
38. Miossec P, Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997, 40:2105-2115. 10.1002/art.1780401203, 9416846.
39. Lubberts E, Joosten LA, Chabaud M, Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, Berg WB. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710. 10.1172/JCI7739, 378501, 10862785.
40. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
41. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657. 10.1016/j.coi.2007.07.020, 2288775, 17766098.
42. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
43. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748. 10.1038/nature01355, 12610626.
44. Miossec P. Diseases that may benefit from manipulating the Th17 pathway. Eur J Immunol 2009, 39:667-669. 10.1002/eji.200839088, 19283719.
45. Steinman L. A rush to judgment on Th17. J Exp Med 2008, 205:1517-1522. 10.1084/jem.20072066, 2442627, 18591407.
46. Page G, Sattler A, Kersten S, Thiel A, Radbruch A, Miossec P. Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 2004, 164:409-417. 1602247, 14742247.
47. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651. 10.1038/nature05505, 17187052.
48. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009, 182:3112-3120. 10.4049/jimmunol.0801967, 19234208.
49. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, Sudo K, Nakae S, Sasakawa C, Iwakura Y. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30:108-119. 10.1016/j.immuni.2008.11.009, 19144317.
50. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, Hippe A, Corrigan CJ, Dong C, Homey B, Yao Z, Ying S, Huston DP, Liu YJ. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007, 204:1837-1847. 10.1084/jem.20070406, 2118667, 17635955.
51. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699. 10.1038/359693a0, 1436033.
52. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
53. Yoshida H, Yoshiyuki M. Regulation of immune responses by interleukin-27. Immunol Rev 2008, 226:234-247. 10.1111/j.1600-065X.2008.00710.x, 19161428.
54. Fitzgerald DC, Rostami A. Therapeutic potential of IL-27 in multiple sclerosis?. Expert Opin Biol Ther 2009, 9:149-160. 10.1517/14712590802646936, 19236245.
55. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569. 10.1038/nature06306, 18033300.
56. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009, 76:10-14. 10.1016/j.jbspin.2008.08.002, 19028128.
57. Burger D, Dayer JM. Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci 2002, 966:464-473. 10.1111/j.1749-6632.2002.tb04248.x, 12114305.
58. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, Kuchroo VK. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-β-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008, 181:2277-2284. 2722959, 18684916.
59. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1α,25-Dihydroxyvitamin has a direct effect on naive D3 CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
60. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, Corrigan CJ, Hickman E, Brown Z, Hawrylowicz CM. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1α,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009, 119:387-398. 2631286, 19139565.
61. Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, Dayer JM. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008, 112:3696-3703. 10.1182/blood-2008-05-155408, 2572797, 18698005.
62. Chabaud M, Aarvak T, Garnero P, Natvig JB, Miossec P. Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions. Cytokine 2001, 13:113-118. 10.1006/cyto.2000.0811, 11145852.
63. Chizzolini C, Chicheportiche R, Burger D, Dayer JM. Human Th1 cells preferentially induce interleukin (IL)-1α while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol 1997, 27:171-177. 10.1002/eji.1830270125, 9022014.
64. Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007, 13:133-134. 10.1038/nm0207-133, 17290270.
65. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008, 121:326-330. 10.1016/j.jaci.2007.10.018, 18061654.
66. Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C. Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra). Ann N Y Acad Sci 2006, 1069:444-453. 10.1196/annals.1351.043, 16855172.
67. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, Woods JM, Haines GK, Ivashkiv LB. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nat Immunol 2002, 3:859-866. 10.1038/ni828, 12172544.
68. Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB. Amplification of IFN-α-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat Immunol 2004, 5:1181-1189. 10.1038/ni1126, 15467722.
69. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB. IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 2006, 24:563-574. 10.1016/j.immuni.2006.02.014, 16713974.
70. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004, 172:6476-6481.
71. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7:454-465. 10.1038/nri2093, 17525754.